![](https://nthumb.tpgimages.com/mid2_com_img/1339/17365/TOP16426693.jpg)
Schematic computer artwork of the monoclonal antibody Blinatumomab, a bi-specific T-cell engagers (BiTEs). Blinatumomab (trade name) specifically targets the CD19 antigen present on B cells. Blinatumomab enables a patient's T cells to recognize malignant B cells. A molecule of blinatumomab combines two binding sites: a CD3 site for T cells and a CD19 site for the target B cells. CD3 is part of the T cell receptor. The drug works by linking these two cell types and activating the T cell to exert cytotoxic activity on the target cell.Blinatumomab is used as a second-line treatment against acute lymphoblastic leukemia. The background is depicting a cancer cell.
px | px | dpi | = | cm | x | cm | = | MB |
Details
Creative#:
TOP16426693
Source:
達志影像
Authorization Type:
RM
Release Information:
須由TPG 完整授權
Model Release:
N/A
Property Release:
N/A
Right to Privacy:
No
Same folder images: